Moderna (NASDAQ:MRNA - Get Free Report) is expected to be posting its quarterly earnings results before the market opens on Thursday, February 27th. Analysts expect Moderna to post earnings of ($2.93) per share and revenue of $977.11 million for the quarter. Individual interested in registering for the company's earnings conference call can do so using this link.
Shares of Moderna stock opened at $35.90 on Thursday. The firm has a market cap of $13.82 billion, a P/E ratio of -3.87 and a beta of 1.59. Moderna has a fifty-two week low of $29.25 and a fifty-two week high of $170.47. The business has a 50-day moving average price of $38.35 and a 200 day moving average price of $53.34.
In other news, insider Shannon Thyme Klinger sold 1,418 shares of the stock in a transaction on Friday, November 29th. The stock was sold at an average price of $42.79, for a total transaction of $60,676.22. Following the completion of the sale, the insider now owns 19,717 shares in the company, valued at approximately $843,690.43. This represents a 6.71 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold 2,664 shares of company stock worth $115,210 over the last ninety days. Company insiders own 15.20% of the company's stock.
Several analysts recently weighed in on the company. Wolfe Research began coverage on Moderna in a report on Friday, November 15th. They issued an "underperform" rating and a $40.00 price objective for the company. Needham & Company LLC reaffirmed a "hold" rating on shares of Moderna in a report on Friday, November 8th. Hsbc Global Res raised Moderna from a "hold" rating to a "strong-buy" rating in a report on Monday, November 18th. Evercore ISI lowered their target price on Moderna from $60.00 to $50.00 and set an "in-line" rating for the company in a report on Monday, January 27th. Finally, Royal Bank of Canada reaffirmed a "sector perform" rating and set a $40.00 target price on shares of Moderna in a report on Tuesday. Four investment analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, three have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $60.63.
View Our Latest Stock Report on Moderna
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
Before you consider Moderna, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Moderna wasn't on the list.
While Moderna currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.